ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Friday, March 20, 2026

5:00PM-6:00PM
Abstract Number: 100
Experience with Janus Kinase Inhibitors and Abatacept in Juvenile Dermatomyositis: A Retrospective Study from a Large Tertiary Center
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 108
Gender Diverse Youth Treatment Response to Amplified Musculoskeletal Pain Syndrome Rehabilitation
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 093
HOW DO WE HANDLE STILL’S DISEASE? REAL-LIFE CLINICIANS’ CHOICES FROM THE METAPHOR PROJECT WORLDWIDE SURVEY
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 110
Juvenile Idiopathic Inflammatory Myopathies and Macrophage Activation Syndrome: A Case Series
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 082
Ophthalmic Predictors of Response to Methotrexate Monotherapy in Pediatric Non-Infectious Uveitis
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 085
Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 124
Patient perspectives, barriers, and next steps in a health care transition clinic for pediatric to adult rheumatology
Posters: Quality, Health Services, and Education Research II
5:00PM-6:00PM
Abstract Number: 111
Pediatric chronic nonbacterial osteomyelitis outcomes after NSAID or TNF inhibitor discontinuation, a registry cohort with two year follow up data
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 102
Positive Affect and Emotion Regulation Protect Juvenile-Onset Lupus and Dermatomyositis Patients from Emotional Distress: Longitudinal Analysis of Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study Parent-Reported Resiliency Data
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 091
Psychosocial Burden in Juvenile Systemic Sclerosis: Insights from PedQL Outcomes
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 131
Reflections on the Creation of a Transition Clinic and the First 6-months of a Registry for Young Adults with Juvenile Idiopathic Arthritis: The Women’s College Hospital Experience
Posters: Quality, Health Services, and Education Research II
5:00PM-6:00PM
Abstract Number: 083
Relative Risk of a Thrombotic Event in Janus Kinase Inhibitor Use for JIA using the Epic Cosmos Database
Posters: Clinical and Therapeutic Aspects II
5:00PM-6:00PM
Abstract Number: 121
Representation of Skin of Color Among Pediatric Images in ACR Image Library
Posters: Quality, Health Services, and Education Research II
5:00PM-6:00PM
Abstract Number: 130
Resilience, Cumulative Social Disadvantage, and Disease Activity in Juvenile Idiopathic Arthritis (JIA)
Posters: Quality, Health Services, and Education Research II
5:00PM-6:00PM
Abstract Number: 095
Rheum2Fake: Lessons from Severe Nutritional Deficiencies
Posters: Clinical and Therapeutic Aspects II
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology